CIK 0000886163 · Large accelerated filer
LIGAND PHARMACEUTICALS INC
Sign in to watch- Tickers
- LGND LGNDZ LGNXZ LGNYZ LGNZZ
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 770160744
- Phone
- 858-550-7500
- Business address
- 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO, CA, 92121
- Former names
- LIGAND PHARMACEUTICALS
Securities
- LGND Common Stock Nasdaq
- LGNDZ Common stock OTC
- LGNXZ Common stock OTC
- LGNYZ Common stock OTC
- LGNZZ Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $6,585,411
- in 7 filings, $4.5M under 10b5-1 plans
Net −$6,585,411. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-02 | Reardon Andrew CLO & Secretary | Grant or award | +4,513 | 41,382 | ||
| 2026-03-02 | Reardon Andrew CLO & Secretary | Grant or award · Employee Stock Option (right to buy) | +21,525 | 21,525 | ||
| 2026-03-02 | KOZARICH JOHN W Director | Sale 10b5-1 | −47 | $197.14 | $9K | 43,140 |
| 2026-03-02 | KOZARICH JOHN W Director | Sale 10b5-1 | −204 | $199.69 | $41K | 42,936 |
| 2026-03-02 | KOZARICH JOHN W Director | Sale 10b5-1 | −41 | $200.40 | $8K | 42,895 |
| 2026-03-02 | KOZARICH JOHN W Director | Sale 10b5-1 | −83 | $201.65 | $17K | 42,812 |
| 2026-03-02 | KOZARICH JOHN W Director | Sale 10b5-1 | −50 | $202.54 | $10K | 42,762 |
| 2026-03-02 | KOZARICH JOHN W Director | Sale 10b5-1 | −42 | $203.57 | $9K | 42,720 |
| 2026-02-15 | Reardon Andrew CLO & Secretary | Shares withheld for taxes | −593 | $183.83 | $109K | 38,662 |
| 2026-02-15 | Reardon Andrew CLO & Secretary | Shares withheld for taxes | −801 | $183.83 | $147K | 37,861 |
| 2026-02-15 | Reardon Andrew CLO & Secretary | Shares withheld for taxes | −992 | $183.83 | $182K | 36,869 |
| 2026-02-15 | Espinoza Octavio Chief Financial Officer | Shares withheld for taxes | −1,026 | $183.83 | $189K | 35,505 |
| 2026-02-15 | Espinoza Octavio Chief Financial Officer | Shares withheld for taxes | −1,223 | $183.83 | $225K | 34,282 |
| 2026-02-15 | Espinoza Octavio Chief Financial Officer | Shares withheld for taxes | −1,270 | $183.83 | $233K | 33,012 |
| 2026-02-15 | Davis Todd C Chief Executive Officer | Shares withheld for taxes | −2,039 | $183.83 | $375K | 195,946 |
| 2026-02-15 | Davis Todd C Chief Executive Officer | Shares withheld for taxes | −4,255 | $183.83 | $782K | 191,691 |
| 2026-02-15 | Davis Todd C Chief Executive Officer | Shares withheld for taxes | −2,805 | $183.83 | $516K | 188,886 |
| 2026-02-14 | Reardon Andrew CLO & Secretary | Grant or award | +6,928 | 37,739 | ||
| 2026-02-14 | Reardon Andrew CLO & Secretary | Shares withheld for taxes | −3,211 | $183.83 | $590K | 34,528 |
| 2026-02-14 | Reardon Andrew CLO & Secretary | Grant or award | +8,810 | 43,338 |
Page 11 of 43 · 858 trades